Cadrenal Therapeutics, Inc. ( (CVKD) ) has released its Q1 earnings. Here is a breakdown of the information Cadrenal Therapeutics, Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for cardiovascular conditions, notably tecarfarin, an oral vitamin K antagonist aimed at improving anticoagulation therapy. The company’s latest earnings report for the quarter ending March 31, 2025, highlights a net loss of $3.8 million, with increased operating expenses primarily due to general and administrative costs and research and development activities. Key financial metrics indicate a decrease in cash and cash equivalents to $7.3 million from $10 million at the end of 2024, alongside a net working capital of $6.1 million. The company has been actively raising funds through its ATM facility, generating additional proceeds post-quarter end. Looking ahead, Cadrenal Therapeutics plans to continue its development efforts and seek further funding to support late-stage clinical trials, with management expressing confidence in their strategic approach to meet future financial needs.